Siamak Daneshmand, MD, moderated “Panel Discussion on Cxbladder Genomic Urine Test for Bladder Cancer” during the International Bladder Cancer Update 2021 virtual conference in April 2021.
This educational activity is sponsored by Pacific Edge Diagnostics.
How to cite: Daneshmand, Siamak. “Panel Discussion on Cxbladder Genomic Urine Test for Bladder Cancer” April 2021. Accessed Oct 2024. https://grandroundsinurology.com/industry-perspective-panel-discussion-on-cxbladder-genomic-urine-test-for-bladder-cancer/
Panel Discussion on Cxbladder Genomic Urine Test for Bladder Cancer – Summary:
Siamak Daneshmand, MD, Professor of Urology and Director of Clinical Research at the University of Southern California (USC), along with Anne Schuckman, MD, Assistant Professor of Clinical Urology at USC, and Sima P. Porten MD, MPH, Associate Professor at the University of California, San Francisco, participate in a panel discussion on the Cxbladder Genomic Urine Test for Bladder Cancer. Dr. Daneshmand reviews a research study that audited the clinical utility of the Cxbladder monitor assay and found that it accurately ruled out patients who did not have recurrent UC, enabling low risk patients to undergo cystoscopy at a longer-than-recommended interval, thereby reducing the cystoscopy burden by 39%. He then interviews Drs. Porten and Schuckman about their experience with Cxbladder, leading the two to discuss ideal patient populations for Cxbladder, in-home sampling procedures, and situations wherein Cxbladder is most effective.
About the International Bladder Cancer Update 2021 virtual conference:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
ABOUT THE AUTHOR
Siamak Daneshmand, MD, is Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as Director of Urologic Oncology, as well as the Urologic Oncology (SUO) Fellowship Director at the University of Southern California (USC) in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve perioperative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the American Urological Association (AUA) guidelines panel for non-muscle invasive bladder cancer, as well as the AUA guidelines panel for testicular cancer. He currently serves as the chair of bladder section of the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials, and has led over a dozen clinical trials in bladder cancer and a pivotal trial in testicular cancer (SEMS). He is currently secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 12 consecutive years. He has been a career leader in academic investigations in bladder cancer and germ cell tumors and was recently appointed as the chair of the SWOG Cancer Research Network local bladder committee. He has been a visiting professor at more than 25 institutions around the world. He has presented over 500 abstracts at scientific meetings and has authored over 375 peer-reviewed articles, reviews, and book chapters.
Dr. Daneshmand earned his medical degree at the University of California, Davis, and completed his residency at the University of Southern California, followed by a two-year fellowship in Urologic Oncology at the University of Southern California’s Norris Comprehensive Cancer Center.